https://www.selleckchem.com/pr....oducts/ZM-447439.htm
airment. Clinicaltrials.gov identifier NCT03289208. Mild to moderate renal impairment had no clinically significant effects on the PK profile of edaravone in Japanese subjects, relative to individuals with normal renal function, and there were no significant safety concerns. Thus, edaravone dosage adjustments are unlikely to be needed in patients with mild to moderate renal impairment. Clinicaltrials.gov identifier NCT03289208. This study aimed to identify patient-related risk factors for chemotherapy-induced nausea and vomiting (CINV
Aimer
Commentaire
Partagez
